Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

8.690 +0.010 (+0.12%)
Streaming Delayed Price Updated: 1:58 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Altimmune
Via Benzinga
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
While their share prices have traveled different paths recently, the similarity between the two companies is striking. 
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
The market for weight loss medicines keeps getting hotter and hotter. 
Via The Motley Fool
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. 
Via InvestorPlace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's Chief Financial Officer. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
Via InvestorPlace
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms
Bitfarms stock is down on Monday after Riot Platforms withdrew its offer for BITF stock in favor of nominating new board memebers. 
Via InvestorPlace
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today. 
Via InvestorPlace
Altimmune Stock Is Rising Monday: What's Driving The Action?
Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes... 
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
From Robbins LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
3 Stocks Under $10 Set to Quadruple by 2025: June Edition
Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst. 
Via InvestorPlace
3 Stocks Quietly Preparing for a 10X Surge: June Edition
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.